New colistin variant outmanoeuvres pathogens

  13 January 2022

The United Nations recently projected that, unless new drugs are developed, multidrug-resistant infections will force up to 24 million people into extreme poverty within the next decade and cause 10 million annual deaths by 2050.

Scientists are especially apprehensive about a broad group of bacteria that circulate in hospitals and can dodge not only blockbuster drugs like penicillin and tetracycline, but even colistin, an antibiotic long used as a crucial last option. When colistin fails, there is often no effective antibiotics for patients with multidrug-resistant infections.

Rockefeller scientists report on the discovery of a compound that could potentially outmanoeuvre colistin resistance. In animal experiments, this prospective antibiotic was highly potent against dangerous opportunistic pathogens like Acinetobacter baumannii, the most common cause of infections in healthcare settings.

Author(s): Tim Sandle
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

More information

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed